The potential M&A deal between pharmaceutical companies Pfizer and AstraZeneca,
previously reported on gtnews
, is off. A final proposal to AstraZeneca from Pfizer to combine the two companies was rejected by the AstraZeneca board, after which Pfizer announced that it does not intend to make an offer for AstraZeneca.
“We continue to believe that our final proposal was compelling and represented full value for AstraZeneca based on the information that was available to us,” said Ian Read, chairman and CEO of Pfizer. “As we said from the start, the pursuit of this transaction was a potential enhancement to our existing strategy. We will continue our focus on the execution of our plans, bringing forth new treatments to meet patients’ needs and remaining responsible stewards of our shareholders’ capital.”
Under the rules governing the takeover of public companies, Pfizer now has to wait six months before making a fresh bid, unless invited to do so by AstraZeneca in the meantime.
Treasurers are being expected to do more work with fewer resources than ever before, so it is little wonder that the automation of day-to-day operations was highly discussed on the second day of EuroFinance, the annual treasury event held in Barcelona this week.
Chicago based Treasury Management System (TMS) vendor GTreasury and Sydney based risk and treasury management vendor Visual Risk have joined forces in a strategic alliance to ... read more
While corporates have more choice when it comes to choosing financial services, the core relationship between banks and businesses hasn't changed, argues Michael Cummins, head of treasury solutions at Citizens Bank.
Plans to overhaul trade finance infrastructure by the R3 consortium, brexit confidence by UK mid-sized businesses and global financial assets hitting a record high all hit the latest headlines in the world of treasury this week.